What is involved in the management of anemia of sickle cells?
genetic condition, in anemia of sickle cells, the patient becomes anemic to reduce functional red blood cells in circulation. As a result of illness, many red blood cells become hard, sticky and deformed in the shape of a crescent. This deformity easily prevents cells from traveling through blood vessels, resulting in painful blocking called crisis . Control of anemia of sickle cells involves blood transfusions, supplements intended to support red blood cell production and bone marrow transplantation.
Red blood cell transfusions can be the main part of the treatment of sickle cell anemia. Transfusions are administered to patients as needed and may be periodic or routine depending on the severity of their disease. Transfusions are complemented by functional red cells and can help prevent crises and suppress the production of sickle cell hemoglobin (HBS). Several risks are associated with this form of management, especially over time, including transinfection and aloimmunization transmitted by fusion where transfused blood PHe genuine antibodies against the patient.
supplements provided to patients in the treatment of anemia of sickle cells include folic acid, hydroxyurea and erythropoietin. Folic acid is necessary during the production of red blood cells, so the supplement can help increase production. This subsequently increases the speed at which the patient complements functional red cells and helps to prevent anemic patient. Patients are generally prescribed one milligram of folic acid daily throughout their lives.
Hydroxyurea is administered to patients with medium to severe anemia sickle cells. The compound is issued in the treatment of sickle -shaped anemia because it increases the production of hemoglobin F, the functional forms of hemoglobin. This increase in hemoglobin can suppress HBS production and reduce both the number, the soleness of the painful crises. Hydroxyurea was once used as chemotherapy, so it has a number of side effects including nausea, vomiting and afterPushing bone marrow.
erythropoietin is a natural hormone in the body that stimulates the production of red blood cells. It occurs naturally in the body and increases during the period of anemia, but providing hormone injections to patients during treatment of sickle cell anemia helps them provide further support. As it naturally occurs in the bone marrow, there are very few related side effects.
Finally, bone marrow transplantation is the only form of treatment of anemia of sickle cells that act as treatment. This form of treatment is usually given to younger patients who are extremely ill. Due to the need and difficulty of finding the corresponding donor, the bone marrow transplantation is not available to all who need them. There are also related risks, including graft-versus host, where transplanted cells attack patients, infection and bleeding. If successful, the life expectancy of the patient will increase significantly.